Having a hard time reading this? VIEW IT ONLINE »
Join us at AHRA
Visit Hologic at AHRA to learn more about Hologic 3D Mammography, low dose 3D mammography options with C-View software and the Affirm 3D biopsy procedure with the Eviva breast biopsy device.
Don't miss the chance to see our new Horizon DXA system and our interventional solutions including the MultiCare Platinum breast biopsy table and optimized ultrasound system with the ATEC breast biopsy device. Plus, learn how your facility can maximize workflow efficiencies with the Trident specimen radiography system.
You’ll also have the opportunity to talk with us and learn how Hologic supports your business — from reimbursement guidance and service programs to education and marketing tools — we’ve got you covered.
Together we can help improve outcomes for women. Learn more at the Hologic exhibit, #316.
Free AHRA Webinar
The Value of Implementing 3D Mammography: A Best Practice Example
Learn more at ahraonline.org/HologicWebinar
  See how Hologic 3D Mammography significantly increases cancer detection.  
  In June, the Journal of the American Medical Association (JAMA)1 published a landmark study evaluating close to half a million mammography exams.  
  up arrow 41% increase in the detection of invasive breast cancers.  
  up arrow 29% increase in the detection of all breast cancers.  
  up arrow 49% increase in Positive Predictive Value (PPV) for a recall.*  
  up arrow 21% increase PPV for biospy.**  
  15% decrease in women recalled for additional imaging.  
  No significant change in the dectection of ductal carcinoma in situ (DCIS).  

Reference: 1. Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM, Barke LD, Greer LN, Miller DP, Conant EF, Breast Cancer Screening Using Tomosynthesis in Combination with Digital Mammography, JAMA June 25, 2014.

* PPV for recall is a widely used measure of the proportion of women recalled from screening that are found to have breast cancer
** PPV for biopsy is a widely used measure of the proportion of women having a breast biopsy that are found to have breast cancer

Hologic, Affirm, ATEC, C-View, Dimensions, Eviva, Horizon, MultiCare, Trident, and associated logos are trademarks or registered trademarks of Hologic and/or Hologic subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to.womenshealth@hologic.com.